Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, published “Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor” as poster presentation from March 12 to 15, 2024 at the 14th World ADC London.

Scroll to Top